INTRODUCTION AND OBJECTIVES:
Greater than 90% of TRUS-guided prostate biopsy cores are histopathologically classified as benign. Optical spectroscopy allows characterization of tumors by measurement of spectral tissue properties. As tissue undergoes malignant growth, the optical properties change. Assessment of changes in tissue optical properties may permit the diagnosis of prostate cancer (PCa) at the time of biopsy. The objective of this study was to acquire and analyze spectral data and correlative tissue biopsy cores using the ClariCore Optical Biopsy System (COBS) for training and development of a prostate tissue classification algorithm.
METHODS: COBS is comprised of a 16-gauge core biopsy needle with an integrated optical sensor and a console which provides real-time prostate tissue classification information prior to tissue collection. Auto advancing of the inner needle via a built-in motor allows tissue classification along the length of the core in 1 mm increments. Men, scheduled for TRUS-guided biopsy with a prostate volume > 20cc were included in this multicenter study. Using COBS, 10-12 tissue biopsy cores were targeted from each patient. Fluorescence spectra at 280 and 340 nm excitations and elastic scattering spectra between 400-750 nm were collected for every core in 1 mm steps. For each tissue core, 1 mm segments were histopathologically classified either as benign or malignant and correlated with respective spectra measurements. RESULTS: Of the 144 patients included in the intent to treat analysis, 142 (98.6%) had biopsy cores successfully collected with the COBS. In total, 1,158 biopsy cores collected with the COBS were used for algorithm development. Of these cores, 185 (16.0%) were found to contain PCa. The COBS algorithm results are provided in Table 1 . During the course of the study no serious adverse events were reported.
CONCLUSIONS: This study demonstrated that COBS can successfully acquire spectral data and correlative tissue biopsy cores for algorithm development. High sensitivity and negative predictive value can be used for precise targeting of PCa lesions with subsequent improvement in the diagnostic yield of TRUS-guided prostate biopsies. The COBS procedure was safe and well-tolerated by patients. Additional studies are underway to further establish accuracy and clinical utility.
Source of Funding: Precision Biopsy Inc., Aurora, CO INTRODUCTION AND OBJECTIVES: Next-generation biomarkers are emerging as valuable tools to improve cancer diagnostics, disease stratification and treatment monitoring. Our group has developed an innovative "liquid biopsy" based on enumeration of submicron cell fragments called extracellular vesicles (EVs) that bear tissue and cancer-specific biomarkers. This approach relies on the use of nanoscale flow cytometry (nFC) allowing high-throughput multiparametric detection and enumeration of particles of events between 100-1000 nm in diameter. Despite the growing interest for developing EV-based blood tests, there is still an unmet need to optimize preanalytical procedures and analytical parameters.
Our team has established the standard operating procedures required for accurate detection of EVs from patient plasmas.
METHODS: We utilized the A50-Micro Plus nanoscale flow cytometer (Apogee FlowSystems Inc.) to identify and measure 100-1000nm sized EVs. Silica and polystyrene beads were used to determine resolution limits of the nFC and established optimal acquisition parameters for EV enumeration. Plasmas from healthy volunteers and cancer patients were used to standardize preanalytical conditions (plasma isolation, storage, handling) and to assess the performance of the nFC.
RESULTS: A50-Micro Plus was capable of detecting EVs from 110 to 1000 nm in a linear manner by using light-scatter and fluorescence detection. Platelet-free plasma, storage temperature (-80C), dilution range (1/15-1/60) are critical considerations to ensure integrity and accurate enumeration of EVs. We used the standard operating procedure to enumerate prostate cancer-derived EVs in prostate cancer patients and unveiled a blood signature which identifies patients with clinically significant prostate cancers.
CONCLUSIONS: We have established a workflow to develop EV-based liquid biopsies using nanoscale flow cytometry. In prostate cancer, we have identified an EV signature that may enhance selective identification of patients with clinically significant prostate cancer and decrease unnecessary tissue biopsies in individuals with absent or low-risk disease. This technique has the potential to facilitate the development of next-generation peripheral blood tests to allow personalized treatment protocols for patients with urogenital cancers.
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